A once-daily 200 mg dose of Inhibikase Therapeutics’ risvodetinib — an oral medication previously called IkT-148009, now undergoing Phase 2 clinical testing — is safe, and can improve motor function and ease activities of daily living in people with previously untreated Parkinson’s disease. That’s according to now…
A first healthy volunteer has been dosed in a Phase 1 clinical trial assessing the safety and tolerability of HL192, an investigational therapy for Parkinson’s disease. The treatment, given orally, is designed to activate Nurr1, a key protein that regulates the development and maintenance of dopaminergic neurons. These nerve…
The American Parkinson’s Disease Association (APDA) received three MM+M awards, including the titanium Best in Show, for its ParkinSex guide to help people with Parkinson’s disease and their partners retain sexual intimacy. Now in its 20th year, the MM+M Awards recognize creativity and effectiveness in…
An informational podcast aims to instruct nursing students in Parkinson’s disease, helping them to feel more empathy for patients and equipping them with the knowledge needed for better Parkinson’s-specific care, a study reports. “By raising awareness of the disease, student nurses will develop an increased understanding, enabling them to…
A five-year project funded by a $5 million National Institutes of Health (NIH) research grant will study how the brain regulates movements, by allowing people with Parkinson’s disease to play video games during brain surgeries. The goal, according to researchers, is to obtain information that can be applied to…
IRLAB Therapeutics is taking steps in preparation for a Phase 3 clinical program of mesdopetam, an experimental medicine for the treatment of levodopa-induced dyskinesia in Parkinson’s disease. The Swedish company is consulting with two advisors, Clintrex and ProPharma Group, to gather the documentation needed to request…
Stem Pharm and Verge Genomics are teaming up to develop a 3D brain model of Parkinson’s disease that uses advanced computational tools to validate new therapeutic candidates. The collaboration will leverage Stem Pharm’s human-derived “mini-brains” that model inflammation of the brain — neuroimmune organoids — and Verge’s…
Damage to the genetic material in mitochondria, cells’ energy production centers, may trigger the spread of nerve cell death in Parkinson’s disease, according to recent research. Faulty mitochondrial DNA (mtDNA) was observed in patient tissues and mouse models. In lab studies, the damaged mtDNA was found to be released…
In recognition of the high level of specialized care it provides to Parkinson’s disease patients, the Ohio State University Wexner Medical Center has been named a Parkinson’s Foundation Comprehensive Care Center, the only hospital center in Ohio with that designation. “The Parkinson’s Foundation Comprehensive Care Center designation symbolizes…
A year of treatment with levodopa plus benserazide led to greater clinical improvements among Parkinson’s disease patients who were also using add-on Azilect (rasagiline), according to a small Chinese study. The use of Azilect was also associated with greater reductions in homocysteine (Hcy), a biomarker associated with…
Get regular updates to your inbox.
